CorMedix(CRMD) - 2025 Q4 - Annual Results

Financial Results - CorMedix Inc. announced preliminary financial results for the quarter and year ended December 31, 2025, which are subject to audit and adjustment[4]. Executive Compensation - The annual base salary of CEO Joseph Todisco increased from $665,000 to $750,000 effective January 1, 2026, with a target annual bonus opportunity rising from 65% to 75% of his base salary[7]. - The Company will provide severance benefits to Mr. Todisco, including continuation of base salary for 18 months and a prorated annual bonus based on actual achievement of specified objectives[8]. Corporate Governance - CorMedix Inc. updated its Board and leadership team on January 8, 2026, as part of its ongoing corporate governance efforts[11]. - The Company is expected to file the full text of the amended employment agreement with its Annual Report on Form 10-K for the fiscal year ended December 31, 2025[10].